|1.||Imai, Toshio: 10 articles (01/2012 - 01/2004)|
|2.||Schäfer, Andreas: 7 articles (06/2015 - 01/2004)|
|3.||Malcangio, Marzia: 7 articles (05/2014 - 05/2008)|
|4.||Bauersachs, Johann: 6 articles (06/2015 - 01/2004)|
|5.||Combadière, Christophe: 6 articles (01/2015 - 01/2007)|
|6.||Clark, Anna K: 6 articles (01/2014 - 05/2008)|
|7.||Murphy, Philip M: 5 articles (01/2015 - 08/2004)|
|8.||Greaves, David R: 5 articles (12/2014 - 11/2003)|
|9.||Manduteanu, Ileana: 5 articles (05/2014 - 12/2008)|
|10.||Calin, Manuela: 5 articles (05/2014 - 12/2008)|
05/01/2009 - "Inflammatory processes in the atria during systemic inflammation remain unclear, so this study tested the hypothesis that macrophages infiltrate the atrial myocardium mainly through the atrial endocardium with the contribution of fractalkine. "
07/01/2002 - "Studies using a static model of adhesion demonstrated CX3CR1/fractalkine interactions accounted for 26% of monocytic THP-1 cell and 17% of peripheral blood natural killer cell adhesion to tubular epithelial cells, suggesting that fractalkine may have a functional role in leucocyte adhesion and retention, at selected tubular sites in acute renal inflammation. "
01/01/2002 - "The purpose of this study was to analyse the expression and distribution of fractalkine in human renal inflammation. "
06/01/2001 - "The results of this study confirm that fractalkine is upregulated at sites of inflammation. "
05/01/2014 - "The chemokine fractalkine (Cx3CL1) and its receptor Cx3CR1 play a pivotal role in recruitment, infiltration and proinflammatory polarization of leukocytes and micoglial cells, however, the role of fractalkine signaling in the development of metabolic inflammation is not fully resolved. "
01/01/2011 - "Furthermore, studies with fractalkine-null transgenic mice indicate that the ablation of the adhesive and chemotactic ligand of CX₃CR1 dramatically impairs the skeletal dissemination of circulating cancer cells. "
04/01/2006 - "The hypothesis of this study is that dendritic cells (DC) genetically modified ex vivo to overexpress fractalkine would enhance the T cell-mediated cellular immune response with a consequent induction of anti-tumor immunity to suppress tumor growth. "
05/01/2005 - "This study suggests that fractalkine can be a suitable candidate for immunogene therapy of cancer because fractalkine induces both innate and adaptive immunity."
10/14/2012 - "Fractalkine (FKN) is a unique cell surface protein with potential as a therapeutic target because of its role in inflammatory diseases and cancer. "
01/01/2011 - "The chemokine Fractalkine/CX(3)CL1 has been widely reported to play a biologically relevant role in tumor growth and spread. "
07/17/2012 - "Previous studies have demonstrated that fractalkine, a newly discovered chemokine, is implicated in spinal cord neuron-to-microglia activation signaling as well as mediation of neuropathic and inflammatory pain via its sole receptor CX3CR1, which is specifically expressed on microglia. "
05/01/2007 - "The present study examined the role of endogenous fractalkine in inflammatory pain. "
04/01/2015 - "Fractalkine levels in SF and serum were both positively associated with self-reported greater pain and physical disability. "
07/02/2013 - "Thus, these results indicate that the inhibition of fractalkine/CX3CR1 signaling in SGCs may serve as a target to control inflammatory pain. "
07/02/2013 - "Fractalkine mediates inflammatory pain through activation of satellite glial cells."
05/01/2005 - "Antagonist of fractalkine (CX3CL1) delays the initiation and ameliorates the progression of lupus nephritis in MRL/lpr mice."
01/01/2015 - "Fractalkine (FKN) is involved in the occurrence and development of human lupus nephritis. "
04/01/2013 - "To investigate the expression of fractalkine (FKN) in the blood and renal tissues of patients with lupus nephritis and explore its significance. "
04/01/2013 - "[Blood and renal fractalkine expression in patients with lupus nephritis and its significance]."
07/01/2007 - "Elevated levels of fractalkine expression and accumulation of CD16+ monocytes in glomeruli of active lupus nephritis."
03/01/2007 - "Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells."
10/18/2005 - "Fractalkine gene therapy for neuroblastoma is more effective in combination with targeted IL-2."
08/01/2002 - "In addition, the regulatory role played by protein kinase C (PKC) in fractalkine secretion in neurons was determined in A1 human hybrid neuronal cell line produced between a human cerebral neuron and a human neuroblastoma cell. "
10/18/2005 - "Here, we tested the hypothesis that chemokine gene therapy with fractalkine (FKN) induces an effective anti-neuroblastoma immune response amplified by targeted IL-2 using the anti-GD2 antibody ch14.18 fused with IL-2 (ch14.18-IL-2). "
|2.||Chemokine CCL2 (Monocyte Chemoattractant Protein 1)
|6.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|7.||Interferon-gamma (Interferon, gamma)
|9.||Messenger RNA (mRNA)
|3.||Homologous Transplantation (Allograft)
|4.||Stem Cell Transplantation
|5.||Angioplasty (Angioplasty, Transluminal)